每经AI快讯，石药集团(01093.HK)涨超6%，截至发稿，涨6.56%，报8.27港元，成交额3.14亿港元。 ...

港股医药生物板块走强，荣昌生物、石药集团、三生制药涨超6%，复宏汉霖、基石药业、中国生物制 药涨幅居前。 ...

Core Viewpoint - The approval of the clinical trial application for ActRIIA/B antibody JMT206 by the company marks a significant advancement in obesity treatment, contributing to a notable increase in stock price [1] Group 1: Company Developments - The stock price of the company increased by 6.56%, reaching HKD 8.27, with a trading volume of HKD 314 million [1] - The clinical trial application for JMT206 was approved on November 25, aimed at treating obesity [1] Group 2: Product Details - JMT206 is a potent ActRIIA/B antibody with an IC50 in the pM range for blocking Actvin A, GDF8, and GDF11-induced ActRIIA/B activation [1] - The preclinical research data for JMT206 was disclosed at ObesityWeek in November, showing cross-species activity in humans, monkeys, rabbits, rats, and mice [1] - In a three-week treatment on mice, weight gain ranged from 8.12% to 22.12%, with weight gain associated with muscle increase [1] - When combined with semaglutide, JMT206 increased fat loss and reduced muscle loss, with a subcutaneous bioavailability of 65% in monkeys [1]

Core Viewpoint - The stock price of CSPC Pharmaceutical Group (01093) has increased by over 6%, reaching HKD 8.27, following the approval of its clinical trial application for the JMT206 injection for obesity treatment [1] Group 1: Clinical Trial Approval - On November 25, CSPC Pharmaceutical Group received approval for the clinical trial application of its ActRIIA/B antibody JMT206, aimed at treating obesity [1] - The company presented preclinical research data for JMT206 at ObesityWeek in November, highlighting its effectiveness as a potent ActRIIA/B antibody [1] Group 2: Mechanism and Efficacy - JMT206 has an IC50 in the pM range for blocking Actvin A, GDF8, and GDF11-induced ActRIIA/B activation, demonstrating cross-species activity across humans, monkeys, rabbits, rats, and mice [1] - In a three-week treatment on mice, JMT206 resulted in a weight increase of 8.12% to 22.12%, with weight gain associated with muscle increase [1] - When combined with semaglutide, JMT206 enhances fat loss while reducing muscle loss, and the subcutaneous bioavailability in monkeys is reported to be 65% [1]

| 股票名称 | 机构名称 | 性质 | 变动前持股 | 变动后持股 | 持股比 | | --- | --- | --- | --- | --- | --- | | 石四药集团 | 曲继广 | 好仓 | 12.22 亿股 | 12.24 亿股 | 41.46%(最新) | | (02005) | | | | | 41.39%(前次) | | 石药集团(01093) | 蔡东晨 | 好仓 | 28.87 亿股 | 28.97 亿股 | 25.14%(最新) | | | | | | | 25.06%(前次) | 智通财经APP获悉，石四药集团(02005)、石药集团(01093)于2025年11月26日进行了最新股东权益披 露。 备注：持股数变动有可能因供股、合股、拆股等情况引起，请注意对照实际情况进行辨别。 ...

格隆汇11月26日丨根据联交所最新权益披露资料显示，2025年11月25日，石药集团(01093.HK)获执行董事兼主席蔡东晨在场内以每股均价7.7935港元增持 1030万股，涉资约8027.31万港元。 增持后，蔡东晨最新持股数目为2,897,284,670股，持股比例由25.06%上升至25.14%。 | 股份代號: | 01093 | | --- | --- | | 上市法國名稱: | 石藥集國有限公司 | | 日期 (日 / 月 / 年): | 26/10/2025 - 26/11/2025 | | 表格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 | | | --- | --- | --- | --- | --- | --- | --- | | | 種 | 原因 | 股份數目 | | （請參閱上述 * 註 | | | | | | | | 产品 份百分比 | | | | | | | | (%) | | | DA20251125E00183 | 10,300,000(L 蔡東晨 | 1101(L ...

Investment Rating - The report maintains an "Outperform" rating for CSPC Pharmaceutical Group [2][12][23] Core Insights - In 9M25, CSPC achieved revenue of CNY 19.9 billion, a year-on-year decrease of 12%, with finished drug revenue at CNY 15.5 billion, down 17% year-on-year [3][16] - The gross profit margin (GPM) was reported at 65.6%, a decline of 4.9 percentage points year-on-year [3][16] - Management anticipates a return to positive growth in finished drug sales by 2026, despite uncertainties surrounding the renewal rules for generic drug procurement [3][16] Financial Performance Summary - Revenue projections for FY25 and FY26 have been adjusted to CNY 27.3 billion and CNY 30.1 billion, respectively, reflecting slower-than-expected out-licensing income recognition [9][23] - Net profit attributable to shareholders is forecasted at CNY 5.0 billion for FY25 and CNY 5.1 billion for FY26, down from previous estimates [9][23] - The company reported a net profit of CNY 3.5 billion in 9M25, a decrease of 7% year-on-year [3][16] Segment Performance - In 3Q25, all segments of finished drugs showed quarter-on-quarter improvement, with total finished drug revenue reaching CNY 4.7 billion, an increase of 8% quarter-on-quarter [5][18] - Notable revenue contributions in 3Q25 included CNY 1.91 billion from the nervous system segment and CNY 0.32 billion from the respiratory system, which saw a 73% year-on-year increase [21][18] Research and Development - R&D expenses for 9M25 were CNY 4.2 billion, an increase of 8% year-on-year, with an R&D expense ratio of 21.0% [3][16] - The company is advancing multiple clinical pipelines, including SYS6010, with clinical data expected to be released in 2026 [20][22] Out-Licensing Opportunities - The report highlights significant potential for out-licensing multiple assets, including SYS6010, which is progressing well in clinical trials [6][19] - The company's business development strategy is entering a phase of tangible results, with expectations for continuous deals that will enhance net profit [6][19]

智通财经APP获悉，香港联交所最新资料显示，11月25日，主席兼执行董事蔡东晨增持石药集团 (01093)1030万股，每股作价7.7935港元，总金额约为8027.31万港元。增持后最新持股数目约为28.97亿 股，最新持股比例为25.14%。 ...

Group 1 - Recent collaboration between Anbiping (688393.SH) and CSPC Pharmaceutical Group (1093.HK) focuses on the development of C-MET companion diagnostics [1] - Anbiping will be responsible for the development of immunohistochemistry companion diagnostic products and the commercialization of IVD/CDx kits, enhancing clinical applications for cancer patients [2] - CSPC Pharmaceutical Group, established in 1997, has maintained double-digit growth in key operational metrics and is recognized for its innovative development in the pharmaceutical industry [3] Group 2 - CSPC has two national key laboratories and over 60 products with annual sales exceeding 100 million, covering APIs, chemical drugs, biological drugs, and functional foods [3] - Anbiping, founded in 2005, is the first listed company in China focusing on pathology diagnostics, with over 200 self-developed immunohistochemistry antibodies and advanced digital + AI-assisted diagnostic products [4] - Anbiping serves over 3,000 medical institutions nationwide through its comprehensive business model that includes tumor screening, pathology diagnosis, smart pathology, and pathology services [4]

Market Overview - A-shares experienced a strong upward movement on November 25, with major indices showing significant gains, particularly the ChiNext Index which rose over 3% at one point [1][2] - By midday, the Shanghai Composite Index increased by 1.13%, the Shenzhen Component Index rose by 2.04%, and the ChiNext Index was up by 2.60% [2] Sector Performance - The communication sector led the gains, with the index surging over 5% during the session. Notable stocks included Dekoli and Guangku Technology, both hitting the 20% limit-up, along with several others achieving over 10% gains [4][6] - The electronics sector also saw a significant rise, with the index increasing by more than 3%. Key performers included Changguang Huaxin, which hit the 20% limit-up, and several other stocks like Tengjing Technology and Haoli Technology, which rose over 14% [7][8] New Listings - A new stock, Hai'an Group, debuted on the market and saw its price surge by over 100% at one point during the session. The company specializes in the research, production, and sales of giant all-steel radial tires for construction machinery [10][12] Hong Kong Market - The Hang Seng Index also showed positive movement, briefly surpassing the 26,000-point mark. Stocks such as Xiaomi Group-W and Alibaba Health saw gains exceeding 5% [13][14] - Xianheng Construction, which recently issued a positive profit forecast, experienced a significant price increase, with its stock rising over 80% during the session [14][17]